Russian diplomat believes Western obsession with Assad leads to dead endRussian Politics & Diplomacy April 27, 10:30
Maria Sharapova wins first match after disqualificationSport April 27, 9:38
Abe expects progress in talks on peace treaty with RussiaWorld April 27, 9:06
Media: Israeli Air Force strike hits area near Damascus airportWorld April 27, 8:35
Russian diplomat believes US strikes on Syria make no military or political senseRussian Politics & Diplomacy April 27, 8:30
Diplomat believes Trump should be given chance to improve relations with RussiaRussian Politics & Diplomacy April 27, 8:10
Twelve militants of Islamic Jihad Mujahideen Jamaat grouping detained in KaliningradSociety & Culture April 27, 2:14
Russian Prosecutor General’s Office finds another 3 NGOs to be undesirableRussian Politics & Diplomacy April 26, 21:42
Moscow ‘seriously concerned’ about Turkish airstrikes in Iraq, SyriaRussian Politics & Diplomacy April 26, 20:55
SAN FRANCISCO, March 2, 2016 /PRNewswire/. Trianni, Inc. (TRIANNI) announces that key aspects of its human antibody mouse platform were issued a patent by the Federal Service for Intellectual Property (ROSPATENT), Ministry of Economic Development of the Russian Federation.
The ROSPATENT allowance covers a transgenic mouse with an engineered endogenous immunoglobulin locus deleted of its variable region gene segments and instead containing arrays of chimeric immunoglobulin gene segments. The chimeric gene segments consist of human immunoglobulin coding sequences and non-coding sequences based on the mouse immunoglobulin variable region locus. They thus confer the capacity to express antibody chains with human variable regions. The patent also covers the methods for generating the mouse.
"We are pleased with the addition of the Russian patent to our patent portfolio," commented Dr. Matthias Wabl, Ph.D., Chairman and CEO of TRIANNI. "This addition further strengthens TRIANNI's position in monoclonal antibody discovery platform."
About Trianni, Inc.
Trianni is a privately held organization, formed in 2010 with a mission to use recent advances in DNA synthesis and genomic modification technology for the development of an optimized therapeutic antibody discovery platform, The Trianni Mouse. The company has research and administrative facilities in the San Francisco Bay Area (CA, USA) and in Research Triangle Park (NC, USA). For more information, please visit www.trianni.com.
Zishan Haroon, MD, PhD
Chief Business Officer
Director of Marketing